Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch Health (BHC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

DiaMedica Therapeutics Inc

iBio

Oncolytics Biotech, Inc.

Outlook Therapeutics Inc

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates.

Why Bausch Health, Oncolytics Biotech, And More Are Moving Today

Investors who have owned stocks since 2016 generally have experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return in the last five years is 131.9%.

$1,000, 5 Years Later: Valeant's Wild Ride To Bausch Health

The shares of Bausch Health Companies Inc (NYSE:BHC) are up 4.3% at $31.41 at last check, after Icahn Capital LP reported a 7.8% stake in the pharmaceutical concern, which is the equivalent of 27.8 million shares.

Pharma Stock Eyes 10th Straight on Shareholder Updates

Bausch Health stock got an added boost Friday after billionaire investor Carl Icahn disclosed a 7.8% stake in the pharmaceutical and medical device company.

Carl Icahn Discloses a Stake in Bausch Health. What It Means for the Stock.

Shares of Bausch Health Companies Inc. rallied 5.8% in premarket trading Friday, putting them on track for a 10th straight gain, after billionaire activist investor Carl Icahn disclosed that he had a acquired 27.8 million share, or 7.83% stake, in the pharmaceuticals and medical devices company. That's enough to make Icahn the company's largest shareholder, according to FactSet data.

Bausch Health rallies toward 10th straight gain after Carl Icahn discloses large stake

LAVAL, QC, Feb. 11, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") issued the following statement in response to the Schedule 13D filed by Icahn Capital LP filed earlier today: Bausch Health's Board of Directors and management team...

Bausch Health Responds To Schedule 13D Filing From Icahn Capital LP

Nicox Investors & Media Contact: Gavin Spencer communications@nicox.com +33 (0)4 97 24 53 00 Mary-Ann Chang mchang@lifesciadvisors.com +44 7483 284 853 Nicox Media France Contact: Sophie Baumont sophie@lifesciadvisors.com +33 6 27 74 74 49

Bausch Health Announces Vyzulta® (latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved in South Korea

LAVAL, Quebec, Jan. 27, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its fourth-quarter and full-year 2020 financial results on Wednesday, Feb. 24, 2021. Bausch Health will host a conference call and live web cast at 8:00 a.m. ET to...

Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2020 Financial Results On February 24

Bausch Health (BHC) and Novaliq GmbH complete enrollment in first of the two phase III studies evaluating NOV03 to treat the signs and symptoms of Dry eye disease associated with MGD.

Bausch Health (BHC) Dry Eye Treatment Study Enrollment Complete

Bausch + Lomb Will Also Host Presentation on Technologies that Can Help Create Efficiencies in Fitting Zenlens™ Scleral Lenses on Patients LAVAL, QC, Jan. 20, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch...

Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium

The healthcare company released a positive preliminary update for the fourth quarter.

Why Bausch Health Stock Jumped 10% Today

JPMorgan Chase & Co

Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at 39th Annual JP Morgan Healthcare Conference (Transcript)

Bausch Health Corp. shares gained more than 5% in after-hours trading Tuesday after the company announced that its annual revenue will come in higher than its guidance. Bausch Health, formerly known as Valeant Pharmaceuticals before a scandal that led to large-scale changes at the company, said that fourth-quarter revenue would top $2.2 billion and lead annual sales to come in higher than the top end of its guidance range, $8 billion.

Bausch Health says annual revenue will exceed guidance, stock gains

LAVAL, QC, Jan. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 10:00 a.m. ET. A...

Bausch Health To Participate At The 39th Annual J.P. Morgan Healthcare Conference

LAVAL, QC, Dec. 30, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland has granted an additional new indication for DEXAVEN...

Bausch Health's DEXAVEN (Dexamethasone Phosphate) Receives New Indication In Poland To Treat Patients With SARS-CoV-2 (COVID-19)

Bausch Health Cos. Inc. said Tuesday it is planning to pay down another $275 million of senior secured term loans, using cash on hand and cash generated from operations.

Bausch Health to repay another $275 million of senior secured term loans

No Debt Maturities or Mandatory Amortization Payments Will Be Due Until 2024 Bausch Health Will Repay Approximately $900 Million of Debt in 2020 LAVAL, QC, Dec. 29, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that on...

Bausch Health To Reduce Debt By $275 Million

Bausch Health has performed very poorly so far in 2020, but it has mostly been due to COVID-19 impacts. The pandemic has affected all of their businesses to varying degrees, but the impacts aren't permanent, and the company doesn't have much debt maturing in the near future.

Bausch Health: Wait For The Spinoff To Invest

Chiasma

Paratek Pharma

The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), position boosts in Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and Bausch Health Companies Inc. (NYSE:BHC) and reductions in its Apple Inc. (NASDAQ:AAPL) and NextEra Energy Inc. (NYSE:NEE) holdings.

The Bruce Fund's Top 5 3rd-Quarter Trades

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Up 13.3% Since Last Earnings Report?

Dr. Reddy's Labs

Teva Pharmaceutical

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

Bausch Health Companies, Inc. (BHC) Presents at Evercore ISI 3rd Annual HealthCONx Conference (Transcript)

Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.

Bausch (BHC) Begins Second Phase III Study on NOV03 for DED

LAVAL, Quebec, Nov. 24, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Bausch + Lomb, its leading global eye health business, announced today that the Company has initiated the second of two Phase 3 studies evaluating the...

News for Bausch Health Companies Inc Stock (BHC)